#Merck

Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.

Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Couric has partnered with Merck to produce a web series about being treated for cancer during the pandemic.

The American Red Cross and the American Cancer Society come together to encourage people to #GiveBloodtoGiveTime.

Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.

Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.

New immunotherapy option approved for uncommon, aggressive type of lung cancer.

First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.

The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.

The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.

Join the Melanoma Research Alliance and share your message with the newly launched With Love, Me program.

Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.

Stop me if you’ve heard this one before.

First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.

A second immunotherapy option is now available for hepatocellular carcinoma.

Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.